ライフサイエンスコーパス: there was no @1 difference in

1 In contrast, there was no difference in 24-hour UFC excretion: 6.91 nmol/m

2 After adjustment for covariates (including surgery), there was no difference in all-cause mortality between Vmax 4

3 Despite markedly different inactivation dynamics, there was no difference in AP parameters across a wide range

4 compared with wild-type bone marrow-derived mast cells, but there was no difference in degranulation when cells were acti

5 By using the Medicare Limited 5% dataset, there was no difference in driving distance between beneficia

6 At postoperative days 3 and 30, there was no difference in estimated glomerular filtration ra

7 igher absolute forces at low isokinetic velocities, whereas there was no difference in force at the highest velocities.

8 However, there was no difference in GA content in tissues between male

9 s of follow-up (HR, 0.79 [95% CI, 0.69-0.91]; P=0.001), and there was no difference in in-hospital morbidity.

10 In addition, there was no difference in mean visual outcome of the first v

11 hen high-flow nasal cannulae were compared with usual care, there was no difference in mortality (high-flow nasal cannula

12 Before program launch, there was no difference in mortality trends between the compl

13 However, there was no difference in nonfatal stroke, cardiovascular di

14 Pneumonia was uncommon, with no differences between groups; there was no difference in other serious adverse events betwe

15 tive function was more frequent with WBRT than with SRS and there was no difference in overall survival between the treat

16 In EGFR FISH-negative tumors, there was no difference in overall survival with gefitinib co

17 Although there was no difference in risk of graft failure across all a

18 ead (95% confidence interval [CI]: -66, -26, P < .001), but there was no difference in sustained reading speeds between g

19 there was no delay between stop and change stimulus, while there was no difference in the 300 ms delay condition.

20 Additionally, there was no difference in the ability of mu-opioid receptor

21 ut task representations in frontal and parietal cortex, but there was no difference in the decoding accuracy of task-rela

22 patients with BVS was higher between 1 and 2 years, whereas there was no difference in the first year.

23 size of tumors was significantly larger in WT mice, whereas there was no difference in the number of alveolar lesions bet

24 However, in 2013, there was no difference in the percentage of patients who ini

25 After adjustment for age and educational level, there was no difference in the postoperative cognitive perfor

26 In a propensity score-matched comparison, there was no difference in the primary end point within 12 mo

27 ary blood flow adjusted for differences in patient factors, there was no difference in the primary end point, death or un

28 Six studies (257 patients) reported rates of any bleeding; there was no difference in the proportions of patients with m

29 sport capacity was also greater in Loda than HS93-4118, but there was no difference in the response of photosynthetic tra

30 While there was no difference in the total amounts of phospholipids

31 r initial shockable rhythms (from 58.9% to 69.2%; P<0.001), there was no difference in unadjusted rate of successful card

32 e for neonatal stool (meconium; Mann-Whitney P > 0.05), and there was no observable difference in community function rega

33 Plaque bacterial communities showed temporal stability, as there was no significant difference in beta diversity values

34 into account the index surgery and the subsequent 90 days, there was no significant difference in cost from either the p

35 In the intention-to-treat analysis, there was no significant difference in disability-free surviv

36 6%) patients in the overall cohort died within 30 days, but there was no significant difference in freedom from chronic l

37 After adjustment, there was no significant difference in in-hospital mortality

38 IL-1beta, IL-4 and IL-2 in both MCI groups (P<0.001), while there was no significant difference in inflammatory markers b

39 For cisplatin-etoposide vs carboplatin-paclitaxel, there was no significant difference in median progression fre

40 ased on a mean follow-up of 3.8 years (range, 0-9.4 years), there was no significant difference in overall mortality or c

41 KRAS wt untreated advanced or metastatic colorectal cancer, there was no significant difference in overall survival betwe

42 With a median follow-up of 31.5 months (IQR 18.9-50.8), there was no significant difference in overall survival betwe

43 At final analysis, there was no significant difference in overall survival for p

44 nd 6 months (26.8% vs. 17.1%; P = 0.007), respectively, but there was no significant difference in reduction between clas

45 In contrast, there was no significant difference in the DOX concentrations

46 roup had neutrophilic capillaritis (54% vs. 29%, P = .035), there was no significant difference in the presence of other

47 minary report of a trial involving patients undergoing PCI, there was no significant difference in the rate of target-ves

48 Comparing tIOLs vs PCRIs, there was no significant difference in the UCDVA, BCDVA, and

49 < 0.00001) were observed for patients undergoing LLR, while there was no statistical difference in mortality.

50 with CRT in cohort one (hazard ratio, 1.35; P = .019), and there was no statistical difference in OS between the sequenc